Paclical drug treating rare cancer types to appear in Russia

Photo

Paclical medicine was approved for the market after it had been tested on patients from 16 countries, about 45% of whom were Russians.

Paclical, the medicine produced by Oasmia Pharmaceutical AB (Sweden) to treat cancer, was issued market authorization in Russia by the Russian Ministry of Health, says the press release of the company.

Paclical is one of the most popular anti-cancer drugs, which is included in the standard course of treatment of various cancer types, such as lung cancer, breast cancer and ovarian cancer. In the USA and the EU, the drug has an orphan status, i.e. it is used to treat rare diseases, such as ovarian cancer. According to the company`s estimates, 225,000 new cases are recorded worldwide.

"Oasmia Pharmaceutical AB announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health," says the press release of the company. Paclical is planned for launch in the second half of 2015.

"It is with great satisfaction that we are finally able to announce the market authorization for Paclical in the Russian Federation and the CIS. Together with our partner Pharmasyntez, we plan to launch Paclical this fall and we hope for a significant market impact," says Julian Aleksov, the CEO of Oasmia Pharmaceutical.

Paclical is a new formulation based on the existing technology of the company Oasmia.

The medicine was approved for the market after it had been tested on patients from 16 countries, about 45% of whom were Russian.

This March, Head of the Federal Antimonopoly Service Igor Artemiev said that the regulatory authority initiates the simplification of the procedure to register foreign drugs in Russia, by discussing the issue of changing the drug trafficking law with Prime Minister Dmitry Medvedev. FAS said that following the order of the Prime Minister, it would work up the way to simplify the licensing of foreign drugs.

Text and pictures by RIA Novosti